AptaBio Therapeutics Inc. announced a private placement of series 1 unregistered non-guaranteed privately placed convertible bonds for a gross proceeds of KRW 38,900,000,000, and 1,037,574 registered convertible preferred shares at a price of KRW 10,698 per preferred share for gross proceeds of KRW 11,099,966,652; for aggregate gross proceeds of KRW 49,999,966,652 on August 16, 2023. The company is raising funding through third-party allotment rights issue for the preferred shares. The transaction has been approved by the board of directors of the company.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
5,650 KRW | -2.42% | -2.25% | -37.57% |
1st Jan change | Capi. | |
---|---|---|
-37.57% | 91.53M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- A293780 Stock
- News AptaBio Therapeutics Inc.
- AptaBio Therapeutics Inc. announced that it expects to receive KRW 49.999966652 billion in funding